Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 1, 2007, Pages 68-73

  Lazic, Ratimir ^a,b   Gabric, Nikica ^a  

^a Eye Clinic Svjetlost   (Croatia)

^b NONE   (Croatia)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Choroidal neovascularization; Pegaptanib

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SIDE EFFECT; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THROMBOEMBOLISM; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34247179981     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0466-4     Document Type: Article

References (28)

1. Polito A, Isola M, Lanzetta P, Gregori D, Bandello F (2006) The natural history of occult choroidal neovascularization associated with age-related macular degeneration. A systematic review. Ann Acad Med Singapore 35:145-150
2. Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two year results of randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Vereporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541-560
3. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123(4):448-457
4. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611
5. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Verteporfin in Photodynamic therapy Study Group (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report no 2. Arch Ophthalmol 121:1253-1268
7. Miller J, Chung CY, Kim RY, MARINA Study Group (2005) Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; July 16-20, Montreal, Canada
8. Bartz-Schmidt KU, Holz FG (2006) Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration. Ophthalmologe 103:461-462
9. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HP, Eter N, Bartz-Schmidt KU, Holz FG (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103:463-470
10. Niemeyer M, Hefner L, Jochmann C, Wiedemann P (2006) Intravitreal Bevacizumab for recurring choroidal neovascularisation. Ophthalmologe (in press)
11. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372
12. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047
13. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368-1370
14. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390
15. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group (2006) Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142:158-160
16. Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Volker M, Holz FG, Bartz-Schmidt KU (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471-475
17. He AR, Marshall J (2005) Biologic therapy for colon cancer. Clin Adv Hematol Oncol 3:555-561
18. Augustin AJ, Schimdt-Erfurth U (2006) Verteporfin therapy with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:14-22
19. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 87:462-468
20. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517-1525
21. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparison of the intraocular tissue distribution, pharmacokinetics, and safety of 125 I-labeled full-length and FAB antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536-544
22. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Verteporfin in Photodynamic therapy Study Group (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report no 2. Arch Ophthalmol 121:1253-1268
23. Shahar J, Avery RL, Heilweil G (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269
24. Meyer CH, Mennel S, Schmidt JC, Kroll P (2006) Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 90:1207-1208
25. Van Wijengaarden P, Costner DJ, Williams KA (2005) Inhibitors of ocular neovascularization: Promise and potential problems. JAMA 293:1509-1513
26. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Luke C, Partsch M, Bartz-Schmidt KU, Szurman P, Tuebingen Bevacizumab Study Group (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 9:1178-1182
27. Manzano RP, Peyman GA, Khan P, Kivilcin M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-261
28. Ignoffo RJ (2004) Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 61 [21 Suppl 5]:S21-S26